This is a proposal for Cedars-Sinai Medical Center to become a Discovery Site for the MAPP Network. We have assembled an exceptional multidisciplinary team, which includes over 20 years of experience in NIH-funded urology research center leadership;a long track record of discovery and hypothesis-driven research and NIH funding in benign urologic conditions;an NIH-funded track record in studies of human subjects;a distinguished record in clinical biomarker discovery based on implementation of state-of-the-art mass spectrometry-based proteomics and related technologies;leadership in research and discovery of complex microbial communities;and translational pathology and biobanking. Cedars-Sinai Medical Center (CSMC) is one of the largest academic medical centers in the western US. Our overall objective is to use state-of-the-art approaches to develop novel strategies for phenotyping and ultimately improving the clinical care of patients with urologic chronic pelvic pain syndromes (UCPPS). The overall hypothesis of this project is that uncultivated commensal microbial communities and their interactions with the host are associated with the development of UCPPS and that the resultant protein patterns in the urine and blood create a signature diagnostic of UCPPS. We will use two complementary approaches to test this hypothesis: (1) We will employ state-of-the-art resources in microbiome genomic sequencing and characterization, some of which are unique to Cedars-Sinai, to define the microbiome/mycobiome of UCPPS patients in comparison to normal subjects, (2) We hypothesize that UCPPS is caused by the changes of some proteins at the expression and post-translational modification levels and that these changes can be rapidly identified in an unbiased manner using advanced proteomics technologies.
The Specific Aims are:
Aim 1. To identify disease-specific changes in bladder commensal bacterial and fungal communities by next generation sequencing of ribosomal DNA in urine from MAPP patients with UCPPS and control subjects.
Aim 2 : To identify clinically relevant non-invasive urinary biomarkers of UCPPS through deep proteomics analysis of urine and blood from MAPP patients. Results from the CSMC team and the multidisciplinary interactions promoted by this proposal will lay the groundwork for innovative collaborative studies on UCPPS within the MAPP network.

Public Health Relevance

Urologic chronic pelvic pain syndromes (UCPPS) are debilitating conditions characterized principally by pain, which affect both women and men. A lack of objective clinical diagnostic criteria has severely affected our ability to adequately idenify and treat UCPPS. The goal of this MAPP discovery site application is to use state- of-the-art genomics and proteomics approaches to develop sensitive and non-invasive diagnostic biomarkers that will allow objective phenotyping of UCPPS patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01DK103260-01
Application #
8776674
Study Section
Special Emphasis Panel (ZDK1-GRB-G (M3))
Program Officer
Mullins, Christopher V
Project Start
2014-09-10
Project End
2019-06-30
Budget Start
2014-09-10
Budget End
2015-06-30
Support Year
1
Fiscal Year
2014
Total Cost
$233,335
Indirect Cost
$96,079
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Yeon, Austin; You, Sungyong; Kim, Minhyung et al. (2018) Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism. Theranostics 8:4520-4534
Kim, Jayoung (2018) Era of the Fourth Industrial Revolution and the Urologists' Journey to Navigating Big Omics Data. Int Neurourol J 22:S101-102
Shahid, Muhammad; Lee, Min Young; Yeon, Austin et al. (2018) Menthol, a unique urinary volatile compound, is associated with chronic inflammation in interstitial cystitis. Sci Rep 8:10859
Jung, Jae Hun; You, Sungyong; Oh, Jae Won et al. (2018) Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. Cancer Lett 437:1-12
Ha, Yun-Sok; Kim, Yeon-Yong; Yu, Na Hee et al. (2018) Down-regulation of transient receptor potential melastatin member 7 prevents migration and invasion of renal cell carcinoma cells via inactivation of the Src and Akt pathway. Investig Clin Urol 59:263-274
Lee, Min Young; Yeon, Austin; Shahid, Muhammad et al. (2018) Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance. Oncotarget 9:13231-13243
Piao, Xuan-Mei; Byun, Young Joon; Kim, Wun-Jae et al. (2018) Unmasking molecular profiles of bladder cancer. Investig Clin Urol 59:72-82
Mansour, Ahmed M; Abdelrahim, Mona; Laymon, Mahmoud et al. (2018) Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer. BMC Urol 18:100
Shahid, Muhammad; Gull, Nicole; Yeon, Austin et al. (2018) Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A. Sci Rep 8:4505
Kutch, Jason J; Ichesco, Eric; Hampson, Johnson P et al. (2017) Brain signature and functional impact of centralized pain: a multidisciplinary approach to the study of chronic pelvic pain (MAPP) network study. Pain 158:1979-1991

Showing the most recent 10 out of 17 publications